Will Biden's FDA Chief Embrace Innovation or Hinder It?

December 16, 2021

By Naomi Lopez

In what may end up being the most colossal bureaucratic red tape blunder this year, President Biden’s nomination for the Food and Drug Administration commissioner is now delayed due to a reported missed paperwork deadline that occurred last month. Dr. Robert Califf’s confirmation hearing to lead the FDA, arguably the nation’s most-important health-related agency during this global pandemic, is now likely delayed until after the new year.

Having previously led the agency under President Obama, Dr. Califf’s track record is well-known. But we live in a world of rapid advances in personalized medicine, wearable technology and ground-breaking treatments — and in this era of growing medical innovation, it’s particularly important that Americans understand the commissioner’s vision for guiding the agency.

Read the rest in The Orange County Register.

Naomi Lopez is the Director of Healthcare Policy at the Goldwater Institute.